Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition

16 Sept 2019

Abstract excerpt

The nucleotide-binding-domain (NBD)-and leucine-rich repeat (LRR)-containing (NLR) family, pyrin-domain-containing 3 (NLRP3) inflammasome drives pathological inflammation in a suite of autoimmune, metabolic, malignant, and neurodegenerative diseases. Additionally, NLRP3 gain-of-function point mutations cause systemic periodic fever syndromes that are collectively known as cryopyrin-associated periodic syndrome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gout, Hyperuricemia, Uric Acid
Share to Heme Oxygenase-1 and Carbon Monoxide
Share to Inflammasome and immune disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31525186
DOI: 10.1371/journal.pbio.3000354

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibitionPMID 31525186Read ↗

MCC950/CRID3 potently targets the NACHT domain of wildtype NLRP3 but not disease-associated mutants for inflammasome inhibitionSemantic proximity Read ↗

Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3Semantic proximity Read ↗

The NLRP3 Inflammasome as a Pharmacological TargetSemantic proximity Read ↗

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disordersSemantic proximity Read ↗

The discovery of NLRP3 and its function in cryopyrin‐associated periodic syndromes and innate immunitySemantic proximity Read ↗

The NLRP3 inhibitor MCC950 inhibits IL-1β production in PBMC from 19 patients with Cryopyrin-Associated Periodic Syndrome and in 2 patients with Schnitzler’s SyndromeSemantic proximity Read ↗

Cryopyrin-associated periodic syndromes: background and therapeuticsSemantic proximity Read ↗

Pathogenic NLRP3 mutants forms constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1β productionSemantic proximity Read ↗

A patent review of NLRP3 inhibitors to treat autoimmune diseasesSemantic proximity Read ↗

CRY-NLRP3 complexes define a circadian checkpoint controlling inflammasome activationSemantic proximity Read ↗

Discovery of a Potent and Selective Inhibitor of Human NLRP3 with a Novel Binding Modality and Mechanism of ActionSemantic proximity Read ↗

Pharmacologic Targeting of PDIA1 Inhibits NLRP3 Inflammasome Assembly and ActivationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.